Company intelligence

CLLS

Cellectis S.A. · NASDAQ · Healthcare

Price$3.10-0.64% · −$0.02

Market cap311.29MEquity value

P / E-4.6Trailing ratio

Volume75.58KLatest session

Market data

CLLS price chart

TradingView

Related signals

1 min delayed

Browse public CLLS signals with their source context and measured market impact. Open any signal for its permanent analysis page.

CLLSDec 16, 2025-1.85% since signal

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday

CLLS shares fell 17.35% after unfavorable arbitration ruling. Allogene retains full control over cema-cel therapy. Cellectis's financial claims were rejected related to trial payments. Partial license termination limits Cellectis to UCART19 V1 product. Allogene targets key clinical analysis in early 2026 for cema-cel.

View signal analysis

Research